MedTrace Logo

A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer

NCT05725343 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2023-02-13

No results posted yet for this study

Summary

Randomized phase III, double-blind, placebo-controlled, multicenter clinical trial.

Conditions

Interventions

DRUG

Canakinumab

Canakinumabwill be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.

DRUG

Placebo

placebo will be administered up to three years, or until lung cancer diagnosis, unacceptable toxicity or physician/subject's decision to withdraw, whichever comes first.

Sponsors & Collaborators

Principal Investigators

  • Andrea De Censi · Ospedali Galliera di Genova

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-03
Primary Completion
2022-04-03
Completion
2022-09-21

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05725343 on ClinicalTrials.gov